|
1
|
Andrés A: Cancer incidence after
immunosuppressive treatment following kidney transplantation. Crit
Rev Oncol Hematol. 56:71–85. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nalesnik MA: Plasma cell tumors in
transplant patients. Blood. 121:1247–1249. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Caillard S, Dharnidharka V, Agodoa L,
Bohen E and Abbott K: Posttransplant lymphoproliferative disorders
after renal transplantation in the United States in era of modern
immunosuppression. Transplantation. 80:1233–1243. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Engels EA, Clarke CA, Pfeiffer RM, Lynch
CF, Weisenburger DD, Gibson TM, Landgren O and Morton LM: Plasma
cell neoplasms in US solid organ transplant recipients. Am J
Transplant. 13:1523–1532. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Karuturi M, Shah N, Frank D, Fasan O,
Reshef R, Ahya VN, Bromberg M, Faust T, Goral S, Schuster SJ, et
al: Plasmacytic post-transplant lymphoproliferative disorder: A
case series of nine patients. Transpl Int. 26:616–622. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Joseph G, Barker RL, Yuan B, Martin A,
Medeiros J and Peiper SC: Posttransplantation plasma cell
dyscrasias. Cancer. 74:1959–1964. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ueda K, Matsui H, Watanabe T, Seki J,
Ichinohe T, Tsuji Y, Matsumura K, Sawai Y, Ida H, Ueda Y and Chiba
T: Spontaneous rupture of liver plasmacytoma mimicking
hepatocellular carcinoma. Intern Med. 49:653–657. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
El Maaroufi H, Doghmi K, Rharrassi I and
Mikdame M: Extramedullary plasmacytoma of the liver. Hematol Oncol
Stem Cell Ther. 5:172–173. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tao K, Zhu X, Xu W, Chen Z and Lu H: A
clinicopathologic and immunohistochemical study of diffuse large
B-cell lymphoma. Zhonghua Bing Li Xue Za Zhi. 31:112–115.
2002.PubMed/NCBI
|
|
10
|
Hu Y, Chen L, Sun CY, She XM, Ai LS and
Qin Y: Clinical significance of chromosomal abnormalities detected
by interphase fluorescence in situ hybridization in newly diagnosed
multiple myeloma patients. Chin Med J (Engl). 124:2981–2985.
2011.PubMed/NCBI
|
|
11
|
Nau KC and Lewis WD: Multiple myeloma:
Diagnosis and treatment. Am Fam Physician. 78:853–859.
2008.PubMed/NCBI
|
|
12
|
Rahmouni A, Divine M, Mathieu D, Golli M,
Dao TH, Jazaerli N, Anglade MC, Reyes F and Vasile N: Detection of
multiple myeloma involving the spine: Efficacy of fat-suppression
and contrast-enhanced MR imaging. AJR Am J Roentgenol.
160:1049–1052. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chinese guidelines for the clinical
application of antibacterial drugs for agranulocytosis with fever.
Zhonghua Xue Ye Xue Za Zhi. 33:693–696. 2012.(In Chinese).
PubMed/NCBI
|
|
14
|
Choi JH, Park BB, Suh C, Won JH, Lee WS
and Shin HJ: Clinical characteristics of monomorphic
post-transplant lymphoproliferative disorders. J Korean Med Sci.
25:523–526. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Opelz G and Döhler B: Lymphomas after
solid organ transplantation: A collaborative transplant study
report. Am J Transplant. 4:222–230. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Salama S, Todd S, Cina DP and Margetts P:
Cutaneous presentation of post-renal transplant lymphoproliferative
disorder: A series of four cases. J Cutan Pathol. 37:641–653. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nalesnik MA: Clinicopathologic
characteristics of post-transplant lymphoproliferative disorders.
Recent Results Cancer Res. 159:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Richendollar BG, Hsi ED and Cook JR:
Extramedullary plasmacytoma-like posttransplantation
lymphoproliferative disorders: Clinical and pathologic features. Am
J Clin Pathol. 132:581–588. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kuppachi S, Naina HV, Self S and Fenning
R: Plasmacytoma-like post-transplantation lymphoproliferative
disorder confined to the renal allograft: A case report. Transplant
Proc. 45:2791–2794. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kamdar KY, Rooney CM and Heslop HE:
Posttransplant lymphoproliferative disease following liver
transplantation. Curr Opin Organ Transplant. 16:274–280. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Trappe R, Zimmermann H, Fink S, Reinke P,
Dreyling M, Pascher A, Lehmkuhl H, Gärtner B, Anagnostopoulos I and
Riess H: Plasmacytoma-like post-transplant lymphoproliferative
disorder, a rare subtype of monomorphic B-cell post-transplant
lymphoproliferation, is associated with a favorable outcome in
localized as well as in advanced disease: A prospective analysis of
8 cases. Haematologica. 96:1067–1071. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McFarlane R, Hurst S, Sabath D, George E
and Argenyi Z: A rare case of plasmacytoma-like post-transplant
lymphoproliferative disorder presenting in the skin of a lung
transplant patient. J Cutan Pathol. 35:599–602. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bidros M, Bauer F, Codreanu I and Dasanu
CA: High-grade solitary extramedullary plasmacytoma arising in
skeletal muscle of a kidney transplant recipient. Leuk Res.
35:e181–e183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Galieni P, Cavo M, Avvisati G, Pulsoni A,
Falbo R, Bonelli MA, Russo D, Petrucci MT, Bucalossi A and Tura S:
Solitary plasmacytoma of bone and extramedullary plasmacytoma: Two
different entities? Ann Oncol. 6:687–691. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Petrucci MT, Tirindelli MC, De Muro M,
Martini V, Levi A and Mandelli F: Extramedullary liver plasmacytoma
a rare presentation. Leuk Lymphoma. 44:1075–1076. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Plant AS, Venick RS, Farmer DG, Upadhyay
S, Said J and Kempert P: Plasmacytoma-like post-transplant
lymphoproliferative disorder seen in pediatric combined liver and
intestinal transplant recipients. Pediatr Blood Cancer.
60:E137–E139. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hanto DW: Classification of Epstein-Barr
virus-associated posttransplant lymphoproliferative diseases:
Implications for understanding their pathogenesis and developing
rational treatment strategies. Annu Rev Med. 46:381–394. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Renoult E, Bertrand F and Kessler M:
Monoclonal gammopathies in HBsAg-positive patients with renal
transplants. N Engl J Med. 318:12051988. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Holmes RD and Sokol RJ: Epstein-Barr virus
and post-transplant lymphoproliferative disease. Pediatr
Transplant. 6:456–464. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Knight JS, Tsodikov A, Cibrik DM, Ross CW,
Kaminski MS and Blayney DW: Lymphoma after solid organ
transplantation: Risk, response to therapy, and survival at a
transplantation center. J Clin Oncol. 27:3354–3362. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Taylor AL, Marcus R and Bradley JA:
Post-transplant lymphoproliferative disorders (PTLD) after solid
organ transplantation. Crit Rev Oncol Hematol. 56:155–167. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Samolitis NJ, Bharadwaj JS, Weis JR and
Harris RM: Post-transplant lymphoproliferative disorder limited to
the skin. J Cutan Pathol. 31:453–457. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mikhael JR, Schuster SR, Jimenez-Zepeda
VH, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL and
Fonseca R: Cyclophosphamide-bortezomib-dexamethasone (CyBorD)
produces rapid and complete hematologic response in patients with
AL amyloidosis. Blood. 119:4391–4394. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rajkumar SV and Kumar S: Multiple myeloma:
Diagnosis and treatment. Mayo Clin Proc. 91:101–119. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Reeder CB, Reece DE, Kukreti V, Mikhael
JR, Chen C, Trudel S, Laumann K, Vohra H, Fonseca R, Bergsagel PL,
et al: Long-term survival with cyclophosphamide, bortezomib and
dexamethasone induction therapy in patients with newly diagnosed
multiple myeloma. Br J Haematol. 167:563–565. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Leiba M, Kedmi M, Duek A, Freidman T,
Weiss M, Leiba R, Nagler A and Avigdor A:
Bortezomib-cyclophosphamide-dexamethasone (VCD) versus
bortezomib-thalidomide-dexamethasone (VTD)-based regimens as
induction therapies in newly diagnosed transplant eligible patients
with multiple myeloma: A meta-analysis. Br J Haematol. 166:702–710.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Reeder CB, Reece DE, Kukreti V, Chen C,
Trudel S, Hentz J, Noble B, Pirooz NA, Spong JE, Piza JG, et al:
Cyclophosphamide, bortezomib and dexamethasone induction for newly
diagnosed multiple myeloma: High response rates in a phase II
clinical trial. Leukemia. 23:1337–1341. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Saboo SS, Fennessy F, Benajiba L, Laubach
J, Anderson KC and Richardson PG: Imaging features of
extramedullary, relapsed, and refractory multiple myeloma involving
the liver across treatment with cyclophosphamide, lenalidomide,
bortezomib, and dexamethasone. J Clin Oncol. 30:e175–e179. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Calvo-Villas JM, Alegre A, Calle C,
Hernández MT, Garcia-Sánchez R and Ramirez G: GEM-PETHEMA/Spanish
MyelomaGroup, Spain: Lenalidomide is effective for extramedullary
disease in relapsed or refractory multiple myeloma. Eur J Haematol.
87:281–284. 2011. View Article : Google Scholar : PubMed/NCBI
|
